fludarabine + antithymocyte globulin

Flu-ATG refers to a combination regimen of fludarabine and antithymocyte globulin (ATG), commonly used as part of reduced-intensity conditioning protocols prior to allogeneic stem cell transplantation, particularly in patients with hematologic malignancies or severe acquired aplastic anemia. Fludarabine is a purine analog that inhibits DNA synthesis, leading to immunosuppression and cytotoxicity against lymphocytes. Antithymocyte globulin is an immunosuppressive polyclonal antibody preparation (derived from rabbit or horse) that targets multiple T-cell surface antigens, resulting in profound T-cell depletion via complement-mediated cytotoxicity and apoptosis. The combination aims to reduce the risk of graft rejection and graft-versus-host disease (GVHD) by suppressing the recipient’s immune response while facilitating engraftment[1][2][4][5].

Other names

Flu-ATG